background
sever
acut
respiratori
syndrom
sar
emerg
china
spread
countri
brought
control
concern
reemerg
deliber
releas
sar
coronaviru
vaccin
develop
initi
evalu
inactiv
whole
viru
vaccin
ferret
nonhuman
primat
viruslikeparticl
vaccin
mice
induc
protect
infect
challeng
anim
exhibit
immunopathologictyp
lung
diseas
design
four
candid
vaccin
human
without
alum
adjuv
evalu
mous
model
sar
vlp
vaccin
vaccin
given
ferret
nhp
anoth
whole
viru
vaccin
rdnaproduc
protein
balbc
mice
vaccin
im
day
sacrif
serum
antibodi
measur
challeng
live
viru
day
day
challeng
mice
sacrif
lung
obtain
viru
histopatholog
result
vaccin
induc
serum
neutral
antibodi
increas
dosag
andor
alum
significantli
increas
respons
signific
reduct
sarscov
two
day
challeng
seen
vaccin
prior
live
sarscov
mice
exhibit
histopatholog
chang
lung
two
day
challeng
includ
anim
vaccin
balbc
given
live
viru
influenza
vaccin
pb
suggest
infect
occur
histopatholog
seen
anim
given
one
sarscov
vaccin
uniformli
immunopatholog
promin
eosinophil
infiltr
confirm
special
eosinophil
stain
patholog
chang
seen
control
group
lack
eosinophil
promin
conclus
sarscov
vaccin
induc
antibodi
protect
infect
sarscov
howev
challeng
mice
given
vaccin
led
occurr
immunopatholog
suggest
hypersensit
sarscov
compon
induc
caution
proceed
applic
sarscov
vaccin
human
indic
sever
acut
respiratori
syndrom
sar
emerg
guangdong
peopl
republ
china
late
spread
countri
asia
canada
ensu
month
infect
control
effort
brought
infect
control
case
includ
almost
death
report
outbreak
period
increas
age
comorbid
risk
factor
sever
diseas
death
sinc
sporad
case
report
howev
possibl
sar
outbreak
could
reemerg
natur
deliber
releas
public
health
concern
sar
caus
coronaviru
sarscov
limit
data
avail
ecolog
sarscov
bat
thought
anim
reservoir
viru
may
transmit
small
mammal
exposur
small
anim
sourc
human
infect
clinic
diseas
similar
sever
acut
respiratori
infect
includ
influenza
sar
case
definit
includ
clinic
epidemiolog
laboratori
criteria
number
therapeut
effort
employ
diseas
asia
canada
howev
treatment
clear
valu
identifi
anim
model
develop
use
mice
hamster
ferret
nonhuman
primat
effort
identifi
use
treatment
effect
vaccin
ongo
vaccin
candid
prevent
sar
develop
variou
group
includ
inactiv
whole
viru
spike
protein
prepar
viruslik
particl
vlp
plasmid
dna
number
vector
contain
gene
sarscov
protein
phase
studi
human
conduct
whole
viru
vaccin
dna
vaccin
earli
concern
applic
sarscov
vaccin
experi
coronaviru
infect
induc
enhanc
diseas
immunopatholog
anim
challeng
infecti
viru
concern
reinforc
report
anim
given
alum
adjuv
sar
vaccin
subsequ
challeng
sarscov
exhibit
immunopatholog
lung
reaction
reminisc
describ
respiratori
syncyti
viru
rsv
infant
anim
model
given
rsv
vaccin
challeng
natur
infant
artifici
anim
rsv
other
describ
similar
immunopatholog
reaction
mice
vaccin
sarscov
vaccin
subsequ
challeng
sarscov
propos
nucleocapsid
protein
sarscov
antigen
immunopatholog
reaction
direct
thu
concern
proceed
human
candid
sarscov
vaccin
emerg
variou
observ
studi
report
conduct
evalu
safeti
immunogen
efficaci
differ
sarscov
vaccin
murin
model
sar
vero
tissu
cultur
obtain
american
type
cultur
collect
atcc
grown
dulbecco
modifi
minimum
essenti
medium
dmem
supplement
penicillin
unitsml
streptomycin
mgml
sodium
bicarbon
fetal
bovin
serum
fb
urbani
strain
sarscov
obtain
tg
ksiazek
center
diseas
control
prevent
atlanta
ga
work
stock
viru
prepar
serial
passag
portion
seed
viru
three
time
vero
cultur
cultur
fluid
infect
cell
clarifi
lowspe
centrifug
filter
mm
filter
aliquot
store
four
differ
sarscov
vaccin
evalu
studi
tabl
two
whole
viru
vaccin
evalu
one
prepar
vero
tissu
cultur
zonal
centrifug
purif
doubleinactiv
formalin
uv
irradi
di
vaccin
div
test
without
alum
adjuv
whole
viru
vaccin
prepar
vero
cell
concentr
purifi
inactiv
beta
propiolacton
packag
alum
adjuv
bpv
recombin
dna
spike
protein
vaccin
sv
produc
insect
cell
purifi
column
chromatographi
test
without
alum
adjuv
fourth
vaccin
vlp
vaccin
viruslik
particl
vaccin
prepar
us
describ
previous
contain
sarscov
spike
protein
nucleocapsid
n
envelop
e
membran
protein
mous
hepat
coronaviru
mhv
sixto
eightweekold
femal
balbc
mice
charl
river
laboratori
wilmington
hous
cage
cover
barrier
filter
approv
biosafeti
level
anim
facil
maintain
univers
texa
medic
branch
utmb
galveston
texa
experi
perform
use
experiment
protocol
approv
offic
research
project
protect
institut
anim
care
use
committe
iacuc
univers
texa
medic
branch
follow
nation
institut
health
unit
state
depart
agricultur
guidelin
three
differ
experi
perform
compar
differ
vaccin
report
adjuv
alum
nonadjuv
pb
vaccin
obtain
nihbei
resourc
group
mice
n
per
group
administ
variou
dosag
vaccin
intramuscularli
im
day
mice
given
pb
alum
trival
inactiv
influenza
vaccin
live
sarscov
includ
control
variou
experi
day
five
mice
group
sacrif
assess
serum
neutral
antibodi
titer
lung
histopatholog
remain
seven
eight
mice
group
challeng
tcid
ml
sarscov
intranas
challeng
mice
euthan
day
determin
viru
quantiti
prepar
lung
tissu
section
histopatholog
examin
mice
anesthet
isofluran
bled
retroorbit
sinu
plexu
heat
inactiv
minut
sera
store
test
assay
virusspecif
neutral
antibodi
perform
serial
dilut
sampl
serum
use
fbsdmem
diluent
tissu
cultur
plate
falcon
final
volum
serial
dilut
sampl
well
ml
addit
tcid
sarscov
ml
well
begin
dilut
serum
dilut
incub
minut
room
temperatur
ml
mixtur
transfer
duplic
well
confluent
vero
cell
microtit
plate
hour
incub
viru
control
well
exhibit
advanc
virusinduc
cpe
neutral
capac
individu
serum
sampl
assess
determin
presenc
absenc
cytopath
effect
cpe
neutral
antibodi
titer
express
reciproc
last
dilut
serum
complet
inhibit
virusinduc
cpe
two
day
post
sarscov
challeng
mice
euthan
lung
remov
lung
lobe
place
neutral
buffer
formalin
histolog
examin
immunohistochemistri
ihc
describ
previous
viru
quantit
remain
tissu
specimen
weigh
frozen
thaw
lung
homogen
pb
fb
solut
use
tissuelys
qiagen
retsch
haan
germani
homogen
centrifug
sarscov
titer
clarifi
fluid
determin
serial
dilut
quadrupl
well
vero
cell
plate
titer
viru
lung
homogen
express
tcid
g
lung
log
minim
detect
level
viru
log
tcid
determin
lung
size
evalu
histopatholog
done
pathologist
mask
vaccinedosag
specimen
sourc
numer
score
assign
assess
extent
patholog
damag
eosinophil
compon
inflammatori
infiltr
neutral
antibodi
titer
lung
viru
titer
histopatholog
lesion
score
eosinophil
infiltr
score
averag
group
mice
comparison
conduct
use
parametr
nonparametr
statist
indic
three
experi
perform
vaccin
dosag
use
control
experi
shown
tabl
vaccin
evalu
immunogen
efficaci
howev
previou
report
immunopatholog
challeng
ferret
nonhuman
primat
vaccin
whole
viru
adjuv
vaccin
mice
vaccin
vlp
vaccin
primari
orient
assess
immunopatholog
among
anim
relat
type
vaccin
dosag
serum
antibodi
respons
viru
infect
vaccin
prepar
made
human
trial
identifi
prepar
like
safe
protect
human
desir
rational
experi
describ
comparison
vaccin
experi
differenti
vaccin
three
vaccin
prepar
simultan
evalu
doubleinactiv
formalin
uv
whole
viru
vaccin
div
rdnaexpress
protein
vaccin
sv
previous
evalu
chimer
virallik
particl
vaccin
vlp
led
immunopatholog
viru
challeng
geometr
mean
serum
neutral
antibodi
titer
group
day
shown
figur
geometr
mean
titer
given
nonadjuv
alum
adjuv
vaccin
differ
doubleinactiv
whole
viru
vaccin
div
vlp
vaccin
student
ttest
differ
protein
vaccin
sv
p
student
test
geometr
mean
titer
differ
dosag
group
given
di
vaccin
div
alum
group
given
protein
vaccin
sv
without
alum
significantli
differ
p
p
p
respect
kruskallw
geometr
mean
dosag
group
given
di
vaccin
div
without
alum
kruskallw
multipl
regress
analysi
postvaccin
titer
di
vaccin
div
significantli
increas
alum
higher
dosag
alum
p
dosag
p
protein
vaccin
sv
alum
increas
respons
p
two
day
challeng
lung
obtain
anim
viru
quantit
histolog
cov
titer
shown
figur
geometr
mean
lung
titer
alum
pb
control
group
tcid
g
respect
vaccin
group
exhibit
lower
titer
detect
viru
day
two
challeng
none
anim
given
alumadjuv
di
vaccin
div
dosag
occasion
anim
lower
dosag
nonadjuv
vaccin
yield
viru
kruskallw
mann
whitney
u
test
comparison
group
given
protein
vaccin
sv
yield
viru
challeng
differ
group
signific
p
group
p
alum
p
adjuv
kruskallw
also
geometr
mean
titer
higher
group
given
lower
vaccin
dosag
geometr
mean
titer
vlp
vaccin
group
similar
vaccin
comparison
experi
lung
lesion
score
histopatholog
grade
individu
anim
scale
repres
degre
cellular
infiltr
repres
degre
bronchiolar
epitheli
cell
necrosi
airway
cellular
debri
figur
shown
anim
exhibit
patholog
chang
challeng
includ
anim
measur
viru
day
two
suggest
viru
infect
occur
detect
day
two
short
durat
infect
neutral
viru
antibodi
lung
process
higher
score
group
relat
primarili
fact
viru
infect
induc
inflammatori
infiltr
epitheli
cell
necrosi
desquam
epithelium
collect
cellular
debri
airway
anim
mean
score
differ
note
among
variou
vaccin
p
anova
group
given
di
vaccin
div
without
alum
higher
mean
score
given
di
vaccin
div
alum
p
mannwhitney
u
similarli
group
given
vlp
vaccin
without
alum
higher
mean
score
given
vlp
vaccin
alum
p
mannwhitney
u
post
hoc
comparison
three
differ
vaccin
indic
di
vaccin
div
group
overal
lower
lesion
score
either
protein
vaccin
sv
group
alum
pb
control
group
p
compar
di
protein
vaccin
div
sv
div
vs
control
group
tukey
hsd
dunnett
respect
vlp
vaccin
group
tukey
hsd
protein
vaccin
group
sv
also
lower
overal
control
group
p
dunnett
characterist
infiltr
compar
anim
given
alum
pb
exhibit
epitheli
cell
necrosi
peribronchiolar
perivascular
mononuclear
cell
infiltr
consist
epitheli
cell
infect
inflammatori
respons
seen
viral
infect
addit
mononuclear
cell
howev
infiltr
among
vaccin
anim
contain
neutrophil
eosinophil
seen
lesion
anim
previous
given
pb
alum
figur
suggest
helper
cell
type
hypersensit
reaction
increas
eosinophil
marker
hypersensit
reaction
percent
eosinophil
lower
vaccin
anim
mean
seen
anim
given
vlp
vaccin
earlier
studi
mean
cell
vlp
pb
alum
respect
studi
eosinophil
seen
lung
infiltr
control
anim
experi
pattern
excess
eosinophil
cellular
infiltr
seen
lung
section
anim
given
vaccin
control
anim
seen
earlier
studi
vlp
vaccin
later
vaccin
although
percent
eosinophil
lower
studi
mean
percent
eosinophil
differ
group
anova
overal
percent
lower
group
given
di
protein
alum
adjuv
vaccin
correspond
nonadjuv
group
p
div
sv
mannwhitney
u
vaccin
eosinophil
mean
percentag
lower
protein
vaccin
sv
either
di
vaccin
div
vlp
vaccin
div
vs
sv
p
vlp
vs
sv
p
tukey
hsd
addit
eosinophil
percentag
three
vaccin
includ
protein
vaccin
significantli
greater
control
sv
div
vlp
vaccin
tukey
hsd
higher
dosag
protein
vaccin
plu
bp
inactiv
whole
viru
vaccin
experi
experi
conduct
verifi
find
initi
experi
hypersensit
immunopathologiclik
reaction
sarscov
challeng
vaccin
anim
determin
higher
dosag
protein
vaccin
sv
would
suppress
infect
still
exhibit
similar
reaction
whether
origin
b
propiolacton
inactiv
whole
viru
vaccin
bpv
shown
immunopathologiclik
reaction
challeng
vaccin
ferret
nonhuman
primat
exhibit
similar
immunopatholog
reaction
mous
model
addit
live
viru
vaccin
group
ad
experi
comparison
challeng
result
follow
vaccin
inactiv
vaccin
follow
earlier
infect
serum
neutral
antibodi
respons
shown
figur
bp
inactiv
vaccin
bpv
avail
one
dosag
alum
smaller
volum
ml
given
one
group
dosag
comparison
geometr
mean
titer
group
given
alum
adjuv
version
di
protein
vaccin
greater
unadjuv
vaccin
div
p
sv
student
test
multipl
regress
analysi
titer
also
significantli
increas
di
protein
vaccin
use
alum
p
dosag
effect
note
geometr
mean
neutral
antibodi
titer
two
bp
inactiv
vaccin
group
bpv
differ
p
mannwhitney
u
two
day
challeng
tcid
sarscov
titer
mice
given
pb
vari
tcid
per
g
tissu
one
vaccin
anim
group
given
protein
vaccin
sv
mg
mg
dosag
without
alum
yield
viru
anim
group
cultur
neg
viru
figur
shown
figur
mean
lesion
score
histolog
evalu
score
system
experi
two
three
develop
replac
pathologist
prefer
scale
correspond
judgment
mild
moder
sever
figur
mean
lesion
score
grade
system
overal
significantli
differ
anova
score
lower
protein
vaccin
either
whole
viru
vaccin
sv
versu
div
bpv
p
respect
tukey
hsd
interest
given
live
viru
challeng
live
viru
two
month
later
exhibit
infiltr
diseas
sever
compar
pb
vaccin
group
despit
detect
viru
day
two
suggest
degre
infect
may
occur
earlier
mean
eosinophil
score
lung
infiltr
lower
protein
vaccin
group
sv
vs
div
sv
vs
bpv
tukey
hsd
howev
clearli
greater
seen
given
pb
live
viru
earlier
tukey
hsd
figur
repres
photo
micrograph
lung
section
mice
experi
two
day
challeng
sarscov
shown
figur
patholog
chang
extens
similar
challeng
group
h
e
stain
perivascular
peribronchi
inflammatori
infiltr
observ
field
along
desquam
bronchial
epithelium
collect
edema
fluid
slough
epitheli
cell
inflammatori
cell
cellular
debri
bronchial
lumen
larg
macrophag
swollen
epitheli
cell
seen
near
lobar
segment
bronchi
small
bronchiol
alveolar
duct
necrot
vascul
promin
medium
larg
blood
vessel
involv
vascular
endotheli
cell
well
tunica
media
includ
lymphocyt
neutrophil
eosinophil
cellular
collect
occasion
multinucl
giant
cell
also
seen
eosinophil
compon
infiltr
promin
anim
vaccin
experiment
vaccin
prepar
compar
anim
mockvaccin
use
pb
expos
earlier
live
viru
figur
eosinophil
seen
lung
section
thu
patholog
seen
section
control
mice
hypersensitivitytyp
patholog
reaction
eosinophil
seen
morpholog
identif
eosinophil
h
e
stain
support
use
giemsa
stain
highlight
intracytoplasm
granul
select
lung
section
shown
confirm
immunostain
antibodi
mous
eosinophil
major
basic
protein
provid
lee
laboratori
mayo
clinic
arizona
differ
group
vaccin
anim
show
similar
trend
sever
patholog
eosinophil
inflammatori
infiltr
howev
div
bpv
prepar
high
dosag
tend
produc
greater
infiltr
eosinophil
vaccin
specif
experi
experi
perform
evalu
vaccin
mous
strain
specif
sarscov
vaccin
use
di
vaccin
div
without
alum
bp
inactiv
vaccin
bpv
contain
alum
highest
dosag
mous
strain
specif
balbc
mice
includ
consist
experi
mice
given
vaccin
dosag
balbc
mice
comparison
mice
exhibit
bia
immunolog
respons
balbc
mice
pb
live
viru
control
includ
trival
formul
influenza
vaccin
dosag
mg
per
compon
given
assess
vaccin
specif
neutral
antibodi
titer
shown
figur
geometr
mean
titer
highest
dose
di
vaccin
higher
vaccin
group
balbc
mice
mice
nonadjuv
di
vaccin
group
significantli
higher
p
mann
whitney
u
serum
antibodi
respons
bpv
live
viru
administr
similar
two
mous
strain
challeng
mean
lung
viru
titer
similar
pb
control
challeng
mice
mous
strain
tcid
g
lung
figur
none
balbc
mous
group
given
either
vaccin
live
viru
earlier
yield
viru
challeng
viru
detect
mice
given
div
without
alum
bpv
alum
versu
balbc
p
mann
whitney
u
mean
lung
lesion
score
two
day
challeng
similar
group
indic
moder
sever
degre
cellular
infiltr
anova
figur
howev
eosinophil
score
significantli
differ
group
anova
significantli
lower
score
nonvaccin
group
vaccin
group
mous
strain
compar
group
comparison
tukey
hsd
eosinophil
score
vaccin
group
differ
two
mous
strain
test
figur
photomicrograph
differ
vaccin
mous
strain
group
shown
figur
vaccin
mous
strain
exhibit
signific
cellular
infiltr
includ
numer
eosinophil
shown
mbp
stain
section
find
consist
hypersensit
compon
patholog
prior
influenza
vaccin
lead
eosinophil
infiltr
lung
lesion
challeng
emerg
diseas
sar
rapid
identif
sever
high
risk
death
prompt
rapid
mobil
control
major
site
occurr
intern
level
part
respons
develop
vaccin
potenti
use
control
potenti
facilit
rapid
identif
caus
agent
new
coronaviru
appli
principl
infect
control
brought
epidem
control
concern
reemerg
natur
deliber
releas
support
continu
vaccin
develop
effort
knowledg
capabl
necessari
prepar
use
effect
vaccin
need
aris
purpos
nation
institut
allergi
infecti
diseas
support
prepar
vaccin
evalu
potenti
use
human
effort
hamper
occurr
initi
preclin
trial
immunopathogenictyp
lung
diseas
among
ferret
cynomolgu
monkey
given
whole
viru
vaccin
adjuv
alum
challeng
infecti
sarscov
lung
diseas
exhibit
characterist
immunopatholog
eosinophil
lung
section
suggest
hypersensit
reminisc
descript
immunopatholog
reaction
young
children
given
inactiv
rsv
vaccin
subsequ
infect
naturallyoccur
rsv
children
experienc
sever
diseas
infect
led
high
frequenc
hospit
two
children
die
infect
conclus
experi
clear
rsv
lung
diseas
enhanc
prior
vaccin
subsequ
studi
anim
model
thought
mimic
human
experi
indic
rsv
inactiv
vaccin
induc
increas
lymphocyt
respons
primarili
cell
occurr
immun
complex
deposit
lung
tissu
type
tissu
respons
associ
increas
type
cytokin
includ
influx
eosinophil
infect
lung
histolog
section
tissu
exhibit
type
respons
notabl
eosinophil
compon
cellular
infiltr
recent
studi
indic
immun
respons
innat
adapt
immun
respons
compon
addit
rsv
experi
concern
inappropri
respons
among
person
vaccin
sarscov
vaccin
eman
experi
coronaviru
infect
diseas
anim
includ
enhanc
diseas
among
infect
anim
vaccin
earlier
coronaviru
vaccin
felin
infecti
periton
coronaviru
fipv
wellknown
exampl
antibodymedi
enhanc
uptak
viru
macrophag
dissemin
increas
viru
quantiti
lead
enhanc
diseas
antigenantibodi
complex
format
complement
activ
also
occur
infect
coronaviru
infect
anim
thu
concern
safeti
administ
sarscov
vaccin
human
becam
earli
concern
vaccin
develop
site
propos
test
vaccin
human
request
given
approv
evalu
differ
vaccin
candid
safeti
effect
two
whole
coronaviru
figur
photomicrograph
lung
tissu
repres
photomicrograph
lung
tissu
unvaccin
unchalleng
mice
normal
balbc
mice
two
day
challeng
sarscov
previous
given
pb
vaccin
live
viru
h
e
immunohistochem
stain
eosinophil
major
basic
protein
perform
describ
figur
h
e
column
left
eo
mbp
column
right
shown
section
normal
mice
vaccin
live
viru
mice
given
pb
vaccin
live
sarscov
challeng
sarscov
shown
middl
bottom
row
imag
although
exposur
sarscov
elicit
inflammatori
infiltr
accumul
debri
bronchial
lumen
eosinophil
group
remain
within
normal
limit
vaccin
one
rdnaexpress
protein
vaccin
vlp
vaccin
prepar
us
evalu
balbc
mous
model
initi
describ
other
sarscov
concern
occurr
lung
immunopatholog
challeng
mice
vaccin
inactiv
viru
vaccin
report
haagman
et
al
ferret
nonhuman
primat
seen
us
challeng
mice
vaccin
sar
vlp
vaccin
find
duplic
experi
report
also
seen
mice
vaccin
rang
dosag
doubleinactiv
whole
viru
vaccin
div
rdna
protein
vaccin
sv
although
immunopatholog
reaction
appear
reduc
among
anim
given
protein
vaccin
compar
given
whole
viru
vaccin
later
experi
find
confirm
vaccin
util
haagman
et
al
also
shown
induc
immunopatholog
mice
thu
four
vaccin
evalu
induc
immunopatholog
howev
four
also
induc
neutral
antibodi
protect
infect
compar
control
challeng
anim
immunopatholog
experi
present
studi
occur
absenc
detect
viru
lung
mice
two
day
challeng
infecti
viru
two
experi
live
viru
group
subsequ
challeng
live
viru
includ
challeng
anim
also
exhibit
similar
histopatholog
chang
challeng
although
infecti
viru
detect
lung
day
two
howev
latter
case
infiltr
nearli
monocyt
lymphocyt
without
eosinophil
compon
seen
vaccin
challeng
anim
separ
test
assess
effect
challeng
inoculum
mice
given
challeng
tcid
inactiv
whole
sarscov
lung
anim
reveal
minim
histopatholog
damag
data
shown
find
suggest
viru
replic
probabl
occur
earli
challeng
includ
anim
given
live
cov
earlier
requir
develop
patholog
includ
immunopatholog
infect
would
transient
limit
detect
two
day
challeng
neutral
lung
homogen
test
viru
nevertheless
immunopatholog
pattern
seen
anim
given
inactiv
vaccin
earlier
cours
experi
report
appear
describ
similar
immunopathologictyp
reaction
promin
eosinophil
sarscov
challeng
balbc
mice
given
venezuelan
equin
enceph
vee
vector
contain
sar
nucleocapsid
protein
gene
challeng
anim
exhibit
infect
similar
unvaccin
anim
well
immunopatholog
similar
experi
vee
vector
contain
gene
exhibit
protect
infect
immunopatholog
recent
group
report
immunopatholog
promin
eosinophil
infiltr
sarscov
challeng
balbc
mice
vaccin
doubleinactiv
whole
viru
vaccin
use
experi
attribut
immunopatholog
reaction
follow
sarscov
vaccin
presenc
nucleocapsid
protein
n
vaccin
anoth
report
vaccinia
use
vector
vaccin
immun
balbc
mice
sarscov
structur
protein
n
membran
envelop
challeng
sarscov
viru
infect
present
group
challeng
reduc
vector
vaccin
group
histopatholog
score
high
n
contain
vector
group
low
contain
group
vehicl
control
group
eosinophil
infiltr
increas
n
vaccin
group
increas
vaccin
group
certain
type
immunopatholog
elicit
protein
vaccin
studi
hope
greater
immun
respons
would
result
higher
dosag
vaccin
induc
greater
protect
infect
well
reduc
prevent
immunopatholog
experi
use
mg
protein
immun
increas
titer
serum
antibodi
induc
viru
detect
day
two
challeng
anim
immunopatholog
occur
challeng
immunopatholog
seen
earlier
vaccin
di
whole
viru
vaccin
seen
experi
also
includ
whole
viru
vaccin
test
earlier
ferret
nonhuman
primat
immunopatholog
initi
seen
vaccin
bpv
report
exhibit
pattern
antibodi
respons
protect
infect
occurr
immunopatholog
challeng
similar
di
whole
viru
vaccin
div
final
experi
conduct
evalu
specif
balbc
mous
compar
mice
exhibit
respons
bia
known
occur
balbc
mice
mice
experi
exhibit
result
challeng
similar
seen
balbc
mice
challeng
anim
given
prior
influenza
vaccin
infect
exhibit
histopatholog
damag
similar
anim
given
pb
earlier
neither
group
exhibit
eosinophil
infiltr
seen
anim
given
sarscov
vaccin
variou
experi
alum
use
adjuv
adjuv
known
promot
type
bia
immun
respons
howev
immunopatholog
seen
vaccinatedchalleng
anim
also
occur
anim
given
vaccin
without
alum
effort
determin
whether
adjuv
induc
bia
respons
would
protect
prevent
immunopatholog
initi
experi
di
pb
suspend
vaccin
adjuv
freund
complet
adjuv
adjuv
howev
experi
abort
septemb
hurrican
ike
induc
flood
galveston
texa
experi
sarscov
whole
viru
vaccin
without
glaxosmithklin
gsk
adjuv
hamster
report
adjuv
thought
induc
immun
respons
author
indic
lung
immunopatholog
seen
among
anim
challeng
includ
group
given
vaccin
without
adjuv
howev
whether
hamster
model
could
develop
immunopatholog
uncertain
final
number
studi
vaccin
anim
model
system
report
presenc
absenc
immunopatholog
challeng
report
summari
sarscov
vaccin
evalu
anim
model
includ
current
report
indic
evalu
immunopatholog
challeng
present
tabl
note
vaccin
contain
protein
induc
protect
infect
studi
vee
vaccinia
vector
contain
n
protein
gene
also
shown
immunopatholog
seen
challeng
vaccin
anim
evalu
immunopatholog
report
except
studi
hamster
gsk
whole
viru
vaccin
thu
inactiv
whole
viru
vaccin
whether
inactiv
formalin
beta
propiolacton
whether
given
without
alum
adjuv
exhibit
immunopatholog
lung
challeng
indic
two
report
attribut
immunopatholog
presenc
n
protein
vaccin
howev
found
immunopatholog
reaction
anim
given
protein
vaccin
although
appear
lesser
intens
thu
immunopatholog
reaction
challeng
vaccin
anim
occur
three
four
anim
model
hamster
includ
two
differ
inbr
mous
strain
four
differ
type
sarscov
vaccin
without
alum
adjuv
inactiv
vaccin
prepar
induc
result
mice
ferret
nonhuman
primat
report
combin
experi
provid
concern
trial
sarscov
vaccin
human
clinic
trial
sar
coronaviru
vaccin
conduct
report
induc
antibodi
respons
safe
howev
evid
safeti
short
period
observ
concern
aris
present
report
immunopatholog
reaction
occur
among
vaccin
individu
exposur
infecti
sarscov
basi
develop
vaccin
sar
addit
safeti
concern
relat
effect
safeti
antigen
variant
sarscov
safeti
vaccin
person
expos
coronavirus
particularli
type
group
studi
vlp
sar
vaccin
contain
n
protein
mous
hepat
viru
boll
et
al
report
immunopatholog
mice
occur
heterolog
cov
vaccin
challeng
concern
eman
propos
n
protein
may
domin
antigen
provok
immunopatholog
reaction
well
document
sever
respiratori
diseas
among
infant
given
inactiv
rsv
vaccin
subsequ
infect
rsv
consid
attribut
immunopatholog
reaction
larg
number
studi
balbc
mous
model
describ
elucid
mani
compon
immunopatholog
reaction
rsv
vaccin
similar
sarscov
vaccin
evalu
balbc
mice
support
caution
clinic
vaccin
trial
sarscov
vaccin
human
interest
similar
occurr
mice
ferret
nonhuman
primat
provid
altern
model
elucid
vaccineinduc
mechan
occurr
immunopatholog
reaction
infect
indic
strong
anim
model
evid
indic
express
n
protein
sarscov
vector
vaccin
induc
sensit
lead
immunopatholog
infect
contrast
result
studi
find
clear
evid
type
immunopatholog
challeng
mice
given
vector
vaccin
protein
find
patholog
studi
anim
immun
rdnaproduc
protein
unequivoc
regard
anim
model
studi
fipv
cat
rsv
mice
indic
viral
surfac
protein
may
sensit
protein
inactiv
vaccin
immunopatholog
infect
suggest
present
protein
vector
format
may
direct
immun
respons
differ
way
sensit
occur
limit
present
studi
includ
perform
mice
uncertainti
relev
rodent
model
sarscov
vaccin
human
addit
intens
studi
viru
replic
includ
quantit
rtpcr
assay
might
confirm
probabl
viru
replic
requir
induct
immunopatholog
vaccin
evalu
mechan
immunopatholog
includ
immunoglobulin
cytokin
respons
vaccin
test
antigenantibodi
complex
tissu
exhibit
reaction
could
strengthen
immunopatholog
find
final
success
studi
adjuv
exhibit
patholog
challeng
would
confirm
bia
immun
respons
well
provid
potenti
safe
vaccin
approach
sar
